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bjectives We evaluated the relative contributions of drug-eluting stent-speciﬁc and background
atural history-driven causes for adverse clinical events between 1 and 5 years, in the paclitaxel-
luting stent (PES) and bare-metal stent (BMS) cohorts of the TAXUS randomized clinical trial
rogram.
ackground Prior studies have demonstrated that clinical events in the ﬁrst year after BMS are pre-
ominantly stent-related but thereafter tend to be driven more by atherosclerotic activity outside
he stented segment. It is not known whether the same is true for PES.
ethods Annualized hazard rates (HRs) were calculated for major adverse events in 1,400 TAXUS
nd 1,397 BMS patients from the randomized and blinded TAXUS I, II, IV, and V trials (median 4.8-
ear follow-up).
esults Although target vessel revascularization (TVR) during the ﬁrst year was driven by target
esion revascularization (TLR), TVR after 1 year involved similar numbers of TLR and non-TLR events.
oreover, the annualized HR for non-target lesion TVR and other major adverse events (including
eath, myocardial infarction, and stent thrombosis) were relatively constant beyond 1 year and not
igniﬁcantly different between PES and BMS.
onclusions The low and similar late HR for many of the observed late events after BMS and PES
uggests that many of the late events after PES reﬂect background disease activity outside the
tented segment rather than stent-related events per se. Analyses of long-term drug-eluting stent
utcomes should recognize and attempt to correct for this background event rate by using suitable
MS control subjects. (J Am Coll Cardiol Intv 2009;2:504–12) © 2009 by the American College of
ardiology Foundation
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505urrent reports on drug-eluting stents (DES) have focused
n their ability to reduce restenosis at the target lesion
ithout increasing short- or long-term adverse safety events
uch as death or myocardial infarction (MI) (1–10). Coro-
ary atherosclerosis, however, is a diffuse and progressive
isease, making it unlikely that focal treatment of any single
oronary artery segment would prevent the continued oc-
See page 513
urrence of adverse events caused by disease progression at
ther (nonstented) sites. The ongoing rates of adverse
ardiac events after DES implantation thus reflect the sum
f events triggered within the stented segment (typically
efined to include 5-mm margins on either end of the stent)
nd those triggered by atherosclerotic disease activity (ste-
osis progression or plaque rupture) outside the stented
egment. In a seminal analysis of bare-metal stent (BMS)
ata, Cutlip et al. (11) showed that, although stent-related
vents predominated during the first year of follow-up, they
ecame less common during years 2 through 5, as natural
istory-driven events outside the stented segment continued to
ontribute importantly to late adverse events. Approximately
ne-half of all target vessel revascularizations (TVRs) that
ccurred in years 2 to 5 were thus due to progression of disease
t nonstented sites (non-target lesion target vessel revascular-
zations [TL TVRs]) rather than failure of the stent and its
argins.
As longer-term follow-up has become available for DES
rials, increasing attention has been paid to late clinical events.
owever, it is important not to attribute all late adverse events
olely to the stents themselves without more clearly under-
tanding which late events are related to the stent itself rather
han to ongoing activity of the underlying coronary artery
isease outside the stented segment. Moreover, late catch-up
n restenosis or effects on the adjacent vessel by DES might
lter the relative proportion of stent-related to nonstent-related
dverse events in comparison with that previously reported for
MS. This study thus compared the ongoing late event rates
n the stented segment and nonstented segments for paclitaxel-
luting stents (PES) and BMS, on the basis of a pooled
nalysis from the TAXUS double-blinded randomized con-
rolled studies.
ethods
atient population and study design. We conducted a
ooled analysis comparing the performance of the TAXUS
xpress paclitaxel-eluting slow-release stent (Boston Scien-
ific Corp., Natick, Massachusetts) with BMS in patients
ith de novo coronary lesions treated in the TAXUS I, II,
V, and V studies (1–4). The TAXUS I, II, and IV trials
nrolled patients with relatively simple de novo lesions,
hereas the TAXUS V trial allowed enrollment of patients pith more complex lesions (e.g., long lesions, smaller
essels). Follow-up is available for TAXUS I (n  61), II
n  266), and IV (n  1,314) through 5 years and for
AXUS V (n  1,156) through 4 years. Consistent
efinitions of clinical end points (TVR, target lesion revas-
ularization [TLR], non-TL TLR, MI, and all-cause mor-
ality) were used by the independent Clinical Events Com-
ittees across the TAXUS trials (1–4). Stent thrombosis
ST) was retrospectively adjudicated for all studies accord-
ng to the Academic Research Council (ARC) definitions
12). The Q-wave myocardial infarctions (QWMIs) were
lassified by the Clinical Events Committee as to their
nvolvement of the target vessel in TAXUS IV and V but
as made by the authors blinded to stent identity (BMS or
ES) in the TAXUS I (0 QWMI) and TAXUS II (7
WMI) trials.
All studies were conducted
ccording to Good Clinical
ractice and were approved by
heir respective institutional re-
iew committees, with all pa-
ients having provided informed
ritten consent.
tatistical analysis. All statistical
nalyses were performed by the
iostatistics Section of Clinical
ciences at Boston Scientific
orporation with SAS version
.0 (Cary, North Carolina). An-
ualized hazard rates (HRs)
ere calculated for TVR, TLR,
on-TL TVR, MI (including
WMI in target and nontarget
essels), all-cause mortality, and
RC definite or probable ST,
ith the person-time method,
xpressed as the event rate/100
atient-years (equivalent to the
ercent event rate/patient/year).
nnualized HRs were calculated for the time periods 0 to 1
ear and 2 to 5 years. Patients with multiple events
ccurring in different time periods were considered to have
he event in each time period (e.g., a patient with MIs at
80 days and 1,000 days would be counted as having an MI
n both the 0- to 1-year period and the 2- to 5-year period).
The approximate Poisson method was used to calculate
he 95% confidence intervals around the annualized HR.
azard rate differences between groups were calculated with
he log-rank test with significance set at p  0.05. Similar
alculations were performed for high-risk subgroups, in-
luding patients with medically treated diabetes, long le-
ions (28 mm), small vessels (2.5 mm), and multiple
tents compared with patients who did not have any of the
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
HR  hazard rate
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
QWMI  Q-wave myocardial
infarction
ST  stent thrombosis
TL TVR  target lesion
target vessel
revascularization
TLR  target lesion
revascularization
TVR  target vessel
revascularization
VLST  very late stent
thrombosisrevious characteristics (low-risk subgroup). Predictors for
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506linical outcomes were assessed with backward step-wise
ox proportional hazards regression with significance set at
 0.05. A value of p  0.1 was required for the variable
o be entered into the model, with the exception of
reatment with PES, which was forced into the model.
Figure 1. Hazard Rates for Clinical Outcomes by Year and Treatment Group
(A) Target vessel revascularization (TVR); (B) target lesion revascularization (TLR
infarction (MI); (E) all-cause mortality; (F) all deathMI; (G) Academic Research
BMS  bare-metal stent(s); PES  paclitaxel-eluting stent(s).esults
Rs for clinical end points during 5 years of follow-up. The
nnualized HR of death and MI were low and similar for
ES and BMS during both the first year and subsequent
he Pooled TAXUS Trials
non-target lesion target vessel revascularization (TL TVR); (D) myocardial
cil (ARC) stent thrombosis (ST) deﬁniteprobable; (H) ARC ST deﬁnite only.for t
); (C)
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507ears 2 to 5, with the exception of an isolated slight increase
n the HR for MI in PES in year 4. Overall, these data are
onsistent with the observation that PES do not increase the
ong-term risk of either death or MI (Figs. 1D to 1F, Table 1).
Hazard rates for ST, both ARC-definite and ARC-
efiniteprobable, were also low and relatively constant.
lthough the annual HR was numerically greater in the
ES compared with the BMS cohort (0.40% vs. 0.22%, p
.12) in years 2 to 5, there was no significant difference
etween BMS and PES throughout the follow-up period
Figs. 1G and 1H). The rates of clopidogrel use were similar
etween groups at hospital discharge and at years 1, 2, 3, 4,
nd 5 (Fig. 2).
epeat revascularization. As previously described, PES
reatment significantly reduced the HR of TVR versus
MS in year 1 and to a lesser extent during year 2 (1– 4).
hereafter, the annualized HR for TVR remained low,
elatively constant, and similar over time between PES
nd BMS (Fig. 1A, Table 1). The early difference in TVR was
riven by the difference in TLR, which thereafter decreased for
oth stent types (Fig. 1B, Table 1). In contrast, the rate of
VR outside the stented segment and its margins (non-TL
VR) was relatively constant at approximately 2%/year in years
to 5, not differing significantly between PES and BMS and
hus more consistent with the natural disease progression
ather than a stent-specific effect (Figs. 1C and 1D, Table 1).
igure 3 demonstrates that these non-TL TVR events con-
ributed equally with TLR to the low ongoing rate of TVR
hat occurs beyond year 1 in both the combined BMS and PES
rms. Similar results were seen when BMS and PES were
nalyzed separately (data not shown).
Table 1. Annualized HRs and Hazard Ratios With 95% CIs for PES and BMS
Year 1
Annualized HR, % (95% CI)
BMS
(n  1,397)
PES
(n  1,400)
Hazard Ra
(95% CI)
TVR 20.4 (17.9–22.9) 11.2 (9.4–13.0) 0.55 (0.45–0.
TLR 17.6 (15.3–19.9) 7.5 (6.0–8.9) 0.42 (0.33–0.
Non-TL TVR 4.5 (3.3–5.6) 4.3 (3.2–5.4) 0.97 (0.68–1.
MI 4.8 (3.6–5.9) 4.2 (3.1–5.4) 0.89 (0.62–1.
QWMI 0.4 (0.1–0.7) 0.7 (0.2–1.1) 1.80 (0.60–5.
Target vessel 0.3 (0–0.6) 0.4 (0–0.8) 1.50 (0.42–5.
Nontarget vessel 0.1 (-0.1–0.2) 0.2 (0–0.5) 3.00 (0.31–28
NQWMI 4.4 (3.2–5.5) 3.5 (2.5–4.6) 0.81 (0.55–1.
Death 1.9 (1.2–2.6) 2.0 (1.2–2.7) 1.04 (0.61–1.
Death or MI 6.4 (5.1–7.8) 6.0 (4.7–7.3) 0.93 (0.68–1.
ARC ST-deﬁnite/probable 0.8 (0.3–1.3) 0.9 (0.4–1.4) 1.09 (0.48–2.
ARC ST-deﬁnite 0.7 (0.2–1.1) 0.7 (0.3–1.2) 1.11 (0.45–2.
ARC  Academic Research Consortium; BMS  bare-metal stent(s); CI  confidence interval;paclitaxel-eluting stent(s); ST stent thrombosis; TLR target lesion revascularization; TVR target vesseWMI rates in target and nontarget vessels. The annualized
ates of overall QWMI, target vessel QWMI, and nontarget
essel QWMI were low and did not differ significantly
etween PES and BMS in either the first year or years 2 to 5
Table 1). Of note, the annualized rate of QWMI in the
on-target vessel (without either a DES or BMS) was similar
o that of QWMI in the PES or BMS stented target vessel.
caling of event rates with markers of diffuse or aggressive
isease. Hazard rates for TVR, TLR, and non-TL TVR
uring years 2 to 5 are generally increased in complex
ubgroups as compared with lower-risk patients without
hese risk factors (Figs. 4A to 4C), although these differ-
nces reached statistical significance only for diabetes
TVR) and for small vessels (TVR and non-TL TVR). The
nnual HRs for all-cause death after 1 year were generally
ow (approximately 1.9%/year) but were significantly in-
reased in patients with diabetes (HR: 2.6, 95% confidence
nterval: 1.9 to 3.3, p  0.01) (Fig. 4D). The annual HRs
or MI also trended upward in the high-risk subgroups of
oth the PES and BMS groups, although it did not reach
tatistical significance (Fig. 4E). The incidence of ARC ST
definiteprobable) in the years 2 to 5 of follow-up were
oo low to allow an accurate comparison of HRs across
ubgroups (Fig. 4F).
Taken together, the observation that the annual HR for
on-TL TVR increases progressively (with parallel trends in
I) in the presence of these markers of diffuse or aggressive
therosclerosis and does so equally for both PES and BMS
uring years 2 to 5 supports these events being driven in
ommon by background disease activity rather than by a
tent-related etiology.
e Pooled TAXUS Clinical Trials
Years 2–5
Annualized HR, % (95% CI)
p Value
BMS
(n  1,349)
PES
(n  1,345)
Hazard Ratio
(95% CI) p Value
0.0001 3.8 (3.2–4.4) 3.3 (2.7–3.8) 0.87 (0.69–1.09) 0.21
0.0001 2.0 (1.6–2.4) 1.6 (1.3–2.0) 0.81 (0.59–1.11) 0.19
0.87 2.1 (1.7–2.5) 1.8 (1.4–2.2) 0.88 (0.65–1.19) 0.41
0.52 0.6 (0.4–0.9) 1.0 (0.7–1.3) 1.59 (0.99–2.55) 0.054
0.28 0.2 (0.1–0.3) 0.3 (0.1–0.4) 1.34 (0.57–3.19) 0.50
0.53 0.1 (0–0.2) 0.2 (0.1–0.3) 2.02 (0.61–6.70) 0.24
0.32 0.1 (0–0.2) 0.1 (0–0.2) 0.80 (0.22–2.99) 0.74
0.28 0.5 (0.3–0.7) 0.7 (0.5–1.0) 1.59 (0.92–2.74) 0.10
0.89 1.8 (1.4–2.2) 1.9 (1.5–2.3) 1.04 (0.77–1.41) 0.79
0.64 2.4 (2.0–2.9) 2.8 (2.3–3.3) 1.15 (0.89–1.49) 0.29
0.83 0.2 (0.1–0.4) 0.4 (0.2–0.6) 1.82 (0.84–3.93) 0.12
0.82 0.2 (0–0.3) 0.3 (0.1–0.4) 1.73 (0.68–4.38) 0.25
azard rate; MI  myocardial infarction; NQWMI  non–Q-wave myocardial infarction; PES in th
tio
67)
53)
39)
27)
38)
32)
.87)
19)
78)
26)
47)
74)
HR  hl revascularization.
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508redictors of clinical outcomes in years 2 through 5. The
ES treatment was forced into the multivariate models and
as not an independent predictor of any of the adverse
utcomes in years 2 to 5 (Table 2). Significant predictors for
VR, non-TL TVR, MI, and death were generally related
o comorbid conditions (including patient risk factors for
oronary artery disease) rather than to lesion-related char-
cteristics or stent type (PES vs. BMS). Moreover, the fact
hat diabetes was a significant predictor of TVR (but not of
LR) further supports the importance of the aggressiveness
f background natural history in driving late events.
Figure 2. Clopidogrel Use Over Time for Patients Treated With DES or BMS
BMS  bare-metal stent(s); PES  paclitaxel-eluting stent(s).
Figure 3. Hazard Rates for TVR and its Components, TLR and Non-TL TVR
Hazard rates for TVR and its components, TLR and non-TL TVR, by year for
the combined BMS and DES groups in the pooled TAXUS trials. Abbrevia-T
tions as in Figure 1.iscussion
he results presented here for randomized PES and BMS
atients parallel the earlier work of Cutlip et al. (11), on the
asis of BMS alone, in demonstrating that many late
dverse cardiac events occurring 2 to 5 years after coronary
tenting are related to disease activity outside the stented
egment rather than late failures of the stented segment
tself. This is an important finding, because many studies of
ES have attributed most or all of the late events to failure
f these devices, with some early studies (13,14) suggesting
ncreased late mortality not confirmed by later analyses
15,16).
The annual rates of death observed in this study beyond
year are similar to those reported by Cutlip et al. (11) in
heir pooled BMS analysis and those reported in coronary
rtery disease patients treated with medical therapy alone
17–23), including studies of primary prevention (24–28).
iven the absence of stents in these patient populations and
he similar rates in PES and BMS arms of the current study,
hese data support the observation that neither BMS nor
ES alter the low annual event rates seen with medical
herapy of stable coronary artery disease and that late death
nd MI after either type of stenting are primarily driven by
he natural history of underlying atherosclerotic disease
ather than by the stent itself.
The same observation can be made regarding late revas-
ularization after stenting. The annual rate of repeat TVR in
ears 2 to 5 remained approximately 3.5% for both PES and
MS in the current study, with fully one-half of all such
VRs beyond 1 year related to disease progression outside
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509f the stented segment (the stent plus 5 mm proximal and
istal margins).
Similarly, the overall annual risk of QWMI is low and
oughly equal in PES and BMS (0.27%/year and 0.20%/
ear, respectively, p  0.50). Approximately one-half of all
ate QWMIs occurred in nonstented vessels (thus com-
letely unrelated to the stent), and annual HRs of cardiac
dverse events (TVR, MI, and death) in years 2 to 5 were
ore closely associated with markers of diffuse or aggressive
oronary artery disease (long lesions or diabetes) than stent
ype, consistent with disease-related rather than stent-
elated (or DES-specific) late events.
It is not clear whether this analysis can be extended to late
Figure 4. Mean  SD HRs by Subgroup for Clinical Outcomes in Years 2 to
(A) TVR; (B) TLR; (C) non-TL TVR; (D) all-cause mortality; (E) MI; (F) ARC ST deﬁ
treated diabetes mellitus; LL  long lesions; SV  small vessels; MS  multiplnd very late stent thrombosis (VLST) after DES. Tenaweser et al. (29) suggested a constant ongoing approx-
mately 0.5%/year ST HR for DES during years 2 to 4 and
ssumed that this finding was unique to DES. Some
eta-analyses have suggested that the frequency of VLST
ight be slightly higher for PES than BMS (30,31) or that
ES might have increased ST events after withdrawal of
hienopyridine treatment (32–34). In contrast, randomized
rials in lower-risk patients comparing DES and BMS have
hown essentially identical ST rates through 1 year and
imilarly low rates of late ST during years 2 through 5
0.25%/year for BMS and 0.35%/year for PES), when the
RC definitions are employed (35). Brar et al. (36) and the
RITON–TIMI 38 trial (Trial to Assess Improvement in
Follow-Up for the Pooled TAXUS (BMS and DES Combined) Trials
robable. p  0.05 versus patients with no risk factors. DM  medically
ts; other abbreviations as in Figure 1.5 of
nite/pherapeutic Outcomes by Optimizing Platelet Inhibition
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510ith Prasugrel–Thrombolysis In Myocardial Infarction)
37) further demonstrate that more prolonged or more
otent thienopyridine therapy can offer similar reduction of
eath, MI, and ST in both DES- and BMS-treated
atients, suggesting a mechanism of benefit more via pro-
ection against natural history-driven (rather than stent-
pecific) events. In fact, 1 study showed a significant
ncrease in death or MI in the 90 days after clopidogrel
iscontinuation for both BMS and medically treated (non-
tented) acute coronary syndrome patients, suggesting that
ncreased cardiac events after clopidogrel withdrawal is not
nique to DES (38). The current study shows years 2 to 5
nnualized HRs (and 95% confidence intervals) for ARC
efinite or probable ST of 0.2 (0.1 to 0.4) for BMS and 0.4
0.2 to 0.6) for PES, with p  0.12 for a difference and p 
.10 for a stent-type effect in multivariate modeling. Absent
ufficiently large and adequately-powered trials comparing
ES with BMS, we cannot exclude that DES might have
differential need for more prolonged dual antiplatelet
Table 2. Multivariate Predictors of Clinical Outcomes
Baseline Variable C
TVR
Age
Diabetes requiring medication
PES treatment*
TLR
Age
Lesion length
Pre-procedure reference vessel diameter
PES treatment*
Non-TL TVR
Diabetes requiring medication
Hypertension treatment
PES treatment*
MI
Current smoker
Prior MI
PES treatment*
All-cause mortality
Age
Current smoker
Hyperlipidemia treatment
Pre-procedure % diameter stenosis
Diabetes requiring medication
PES treatment*
ARC ST (deﬁniteprobable)
Age
LAD lesion location
PES treatment*
*Indicates variable was forced into the model.
Abbreviations as in Table 1.herapy to protect against potentially delayed or incomplete cealing (39). By the same token, neither can we assume
without suitable BMS control subjects) that all ARC-
efined VLST events occurring after DES reflect thrombo-
is initiated by the stent as opposed to natural history-driven
laque rupture occurring outside of the stented segment.
In that regard, 1 interesting finding of the current study
s that the rate of QWMI in nonstented vessels was 0.09%
o 0.11%/year and thus of the same magnitude as the rate of
WMI observed in BMS- or PES-treated vessels. Neither
he ARC definite or probable ST definitions nor, in many
ases, acute angiography can definitively distinguish
hether the causative thrombus has been initiated within
he stent (perhaps due to incomplete healing, poor apposi-
ion, or local inflammation) or by a ruptured plaque in the
djacent vessel outside the stent. The MIs resulting from
laque rupture would thus count as ARC ST (even if no
tent were present), and their occurrence might explain
ome of the VLST events observed in BMS that are
resumably well-healed by 1 year after implantation. Studies
g Years 2 Through 5 in the Pooled TAXUS Trials
ient
Hazard Ratio
(95% CI) p Value
2 0.98 (0.97–0.99) 0.004
8 1.32 (1.02–1.69) 0.03
4 0.87 (0.69–1.10) 0.24
3 0.97 (0.96–0.99) 0.001
2 1.02 (1.00–1.04) 0.03
4 0.71 (0.52–0.97) 0.03
0 0.82 (0.60–1.12) 0.20
6 1.59 (1.15–2.19) 0.005
0 1.49 (1.01–2.19) 0.04
4 0.87 (0.64–1.18) 0.37
4 2.10 (1.30–3.42) 0.003
0 1.82 (1.14–2.90) 0.01
2 1.52 (0.95–2.45) 0.08
6 1.06 (1.05–1.08) 0.001
4 2.10 (1.43–3.08) 0.001
7 0.63 (0.46–0.86) 0.004
2 0.98 (0.97–1.00) 0.02
5 1.60 (1.06–2.31) 0.02
4 0.96 (0.71–1.31) 0.80
4 0.96 (0.92–0.99) 0.02
0.37 (0.15–0.91) 0.03
5 1.91 (0.88–4.14) 0.10Durin
oeffic
0.0
0.2
0.1
0.0
0.0
0.3
0.2
0.4
0.4
0.1
0.7
0.6
0.4
0.0
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511hus be needed to understand the relative roles of stent-
pecific DES VLST versus natural history-driven events
nd the potential benefit of more prolonged dual antiplatelet
herapy against each problem (40).
There are several limitations to the current analysis. First,
ith the exception of the TAXUS V trial (which included
essels as small as 2.25 mm and lesions as long as 38 mm),
nly patients with relatively uncomplicated lesions were
ncluded. The results of this study thus might not be fully
pplicable to a broader patient population, although patients
ith more advanced disease would likely have an even
reater relative contribution from natural history-driven
vents. By the same token, these results should not be
ompared directly with natural history studies that have not
ncluded more complex TAXUS V-like lesions. Second,
vent adjudication for the longer follow-up intervals (after 1
ear) was more difficult, because of a limited ability to
eparate cardiac death from all-cause death, greater difficulty
n determining the cause of late MIs, and reliance on the
ore angiographic laboratory to separate TLR from non-TL
VR. Third, there was not tight control of the use of
cetylsalicylic acid or clopidogrel after 1 year to ascertain the
otential benefit of sustained dual antiplatelet therapy on
ate cardiac events. By virtue of the double-blind design of
he included studies, however, the dual antiplatelet therapy
sage patterns remained comparable for PES and BMS
hroughout the follow-up period. Fourth, the TAXUS
linical trial program was not specifically designed to eval-
ate these low rates of late adverse events and would not be
owered to detect small differences in these rates. Nonethe-
ess, this is the largest randomized cohort of DES patients
ith long-term follow-up, and the analysis does provide
nique insights into the relationship of late cardiac adverse
vents with DES versus BMS and the relative roles of
tent-specific and natural history-driven late events. Similar
ata on long-term follow-up with DES versus BMS are
nly available for the Cypher sirolimus-eluting stent (Cor-
is, Johnson & Johnson Company, Miami Lakes, Florida)
41) and show analogous findings to the current study.
onclusions
hese data suggest that PES significantly reduce TLR
stent and 5 mm proximal and distal margins) during the
rst year after procedure but that they do not reduce the late
ngoing 2% to 4% annual rate of repeat revascularization of
he target vessel due to disease progression outside the
tented zone. Late ongoing non-TL TVR, death, MI, and
o some extent ARC-defined VLST occur at roughly equal
ates in both DES and BMS but are increased in patients
ith markers of more diffuse or aggressive atherosclerosis.
linical trials attempting to evaluate long-term DES out-
omes must recognize and attempt to correct for these
nderlying natural history-driven events by using suitableMS control subjects. At the same time, we should con-
inue our efforts to develop pro-healing, next-generation
ES designs that might reduce any DES-specific late
vents stemming from delayed or incomplete stent strut
overage.
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